Wang Xiaochun, Batty Kathleen M, Crowe Philip J, Goldstein David, Yang Jia-Lin
Sarcoma Nano-Oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales (UNSW) , Sydney, NSW , Australia ; Department of Surgery, Prince of Wales Clinical School, University of New South Wales (UNSW) , Sydney, NSW , Australia.
Sarcoma Nano-Oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales (UNSW) , Sydney, NSW , Australia ; Department of Medical Oncology, Prince of Wales Clinical School, University of New South Wales (UNSW) , Sydney, NSW , Australia.
Front Oncol. 2015 Jan 28;5:2. doi: 10.3389/fonc.2015.00002. eCollection 2015.
Hyper-activation of the HER (erbB) family receptors, HER 1-4, leads to up-regulation of the three vital signaling pathways: mitogen activated protein kinase, phosphoinositide 3-kinase/AKT, and Janus kinase/signal transducer and activator of transcription pathways. Blocking HER1/EGFR has a limited anticancer effect due to either secondary mutation e.g., T790M or by-pass signaling of other HER members. The emergence of an anti-panHER approach to blockade of these pathways as a cancer treatment may provide a solution to this resistance. This review aimed to provide an overview of the HER signaling pathways and their involvement in tumor progression and examine the current progress in panHER inhibition.
Recent literature associated with HER signaling pathways and panHER inhibition was reviewed through PubMed and Medline database, followed by critical comparison and analysis.
Pre-clinical studies and clinical trials of panHER inhibitors show promising results, and the potential to improve patient outcomes in solid cancers.
The use of panHER inhibitors in cancers with HER-family hyper-activation, such as other epithelial cancers and sarcoma, is a new direction to research and has potential in clinical cancer therapy in the future.
HER（erbB）家族受体1-4的过度激活会导致三种重要信号通路的上调：丝裂原活化蛋白激酶、磷酸肌醇3激酶/AKT以及Janus激酶/信号转导及转录激活因子通路。由于继发突变（如T790M）或其他HER家族成员的旁路信号传导，阻断HER1/表皮生长因子受体（EGFR）的抗癌效果有限。作为一种癌症治疗方法，采用抗泛HER方法来阻断这些信号通路可能为这种耐药性提供解决方案。本综述旨在概述HER信号通路及其在肿瘤进展中的作用，并探讨泛HER抑制的当前进展。
通过PubMed和Medline数据库检索与HER信号通路和泛HER抑制相关的近期文献，随后进行批判性比较和分析。
泛HER抑制剂的临床前研究和临床试验显示出了有前景的结果，以及改善实体癌患者预后的潜力。
在HER家族过度激活的癌症（如其他上皮癌和肉瘤）中使用泛HER抑制剂是一个新的研究方向，并且在未来临床癌症治疗中具有潜力。
Zotero 插件